Canrenoate (K)

Canrenoate (K) is a potassium-sparing diuretic with action and uses similar to those of spironolactone. Canrenoate (K) is used in the treatment of refractory oedema associated with heart failure or hepatic disease.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Carboxylic acid lactone. . The Molecular Weight of Canrenoate (K) is 396.20. Its pKa is 5.2.
Contraindications
Canrenoate (K) is contraindicated in conditions like Hyperkalaemia,Renal impairment.
Effects
The severe or irreversible adverse effects of Canrenoate (K), which give rise to further complications include Hyperkalemia, Change in voice.The signs and symptoms that are produced after the acute overdosage of Canrenoate (K) include Nausea, Vomiting, Hallucinations, Restlessness, Hyperkalemia, Transient confusion.The symptomatic adverse reactions produced by Canrenoate (K) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Gynecomastia, Menstrual irregularity, Pain at injection site.
Indications
Canrenoate (K) is primarily indicated in conditions like Magnesium deficiency, Oedema with secondary aldosteronism, Potassium deficiency, Primary hyperaldosteronism.
Interactions
No data regarding the interactions of Canrenoate (K) was found.
Interfrence
Measurement of Serum Digoxin by Immunoassay.
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
IV inf Store at room temperature. Protect from Sunlight. Use within 12 hrs if kept at room temperature.
Warnings
Serum electrolytes and blood urea nitrogen should be measured periodically. It should be used carefully in patient who are at increased risk of developing hyperkalemia, such as elderly, those with diabetes mellitus and those with some degree of renal or hepatic impairment and patients likely to develop acidosis.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.